Pharmacovigilance Inspections Time to panic? Marie-Odile Hendrickx, DVM, MRCVS Pfizer Animal Health 13 December 2010

Size: px
Start display at page:

Download "Pharmacovigilance Inspections Time to panic? Marie-Odile Hendrickx, DVM, MRCVS Pfizer Animal Health 13 December 2010"

Transcription

1 Pharmacovigilance Inspections Time to panic? Marie-Odile Hendrickx, DVM, MRCVS Pfizer Animal Health 13 December 2010

2 Content Legal basis What do agencies want? What happens Before During After How do you prepare for it? Industry wishes Conclusions 2

3 Did you say Inspections? Legal basis: Directive 2001/82/EC Art 80 Role of the MAH: to have an appropriate system of Pharmacovigilance (PhV) Role of the Agency & Competent Authorities: to verify, on behalf of the community that the MAH satisfies the requirements as laid down in this Directive and its amendments (Directive 2004/28/EC) MONITORING of COMPLIANCE 3

4 Inspections for what? - 1 Routine inspections Targeted inspections when triggers are reached No specific concerns Specifics concerns Inspections of contractors, licensing partners The agencies want reassurance that the MAH are fulfilling their obligations regarding the PhV requirements laid down by the legislation 4

5 Inspections for what? - 2 To improve post marketing surveillance To help and advise MAHs as necessary If severe breaches are observed repeatedly penalties can be imposed 5

6 What happens? Before the inspection Notice usually given by agency, a few weeks to a few months Information may be requested prior to the inspection SOPs and other procedures Information from DDPS Listing of expedited cases for a given period Calendars of PSURs for compliance with 60 days Third party agreements Product related issues Agreement on logistics, participants, inspection plan 6

7 What happens? During the inspection -1 Opening meeting Introductions Attendees: Inspector(s), PhV staff, QA staff, Management Objectives and the remit of the inspection are agreed Inspection itself, can be a few hours to a few days, ensure that you have a room allocated for the inspectors and staff who know what their role is 7

8 What happens? During the inspection -2 May include Review of PhV cases, documentation and processes: reconstruction of a case, from original data collection, through follow up to reporting PSURs elaboration and risk benefit assessments Review of procedures and their application Interviews with staff involved in all PhV activities, from receptionists to sale reps Review of staff training records, CV, job descriptions 8

9 What happens? During the inspection -3 And Demonstration of the database, looking at maintenance, archiving, security and disaster recovery processes Third party contracts Quality Management system in place Review of archives Process for literature reviews 9

10 What happens? During the inspection -4 Exit Meeting Attendees include the Inspector(s), QA Management, PhV staff and Management To ensure an understanding of findings, not to debate Can provide updates or correct misinformation 10

11 What happens? During the inspection -5 Opportunity to respond to findings as appropriate (some issues may need to be discussed internally prior to making a commitment for follow-up) No written list of findings at this stage but all findings will be described by the inspector Agreement on next steps: the issue of the inspection report 11

12 What happens? After the inspection Inspections draft report issued for comments Final report usually within 4 weeks of inspection Can be a listing of deficiencies classified in critical, major and minor, comments and recommendations, Can be a statement of compliance or non compliance and the issues to be addressed Response from MAH expected usually within 30 days with response plan to address issues If critical findings, may warrant a follow up inspection 12

13 How to prepare for an inspection? -1 Not a last minute activity, should be addressed as part of the Quality Management of PhV Use the guidance provided by legislation, Guidelines, QA teams Quality management system in place SOPs and procedures Training of all concerned staff Regular internal audits of PhV activities and systems should ensure that gaps, issues are identified and addressed Would recommend every 2-3 years Anytime when there is a major change in the PhV system Internal audit prior to a planned inspection Ensure suitable management involvement 13

14 How to prepare for an inspection? - 2 As soon as you are notified Inform your QA group and management and request their presence on the day(s) of inspection Book meeting rooms and assign tasks Ensure the availability of key people (EUQP for example) on the day and adequate resources for dealing with the paperwork Contact inspectors and engage communication 14

15 How to prepare for an inspection? - 3 Other activities May run a refresher to your staff Recommend an internal audit if last one was a while ago Address any easy fix findings Don t make major changes to procedures just prior to the inspection but show that you have identified some issues and your plans to address them Training of concerned staff prior to inspection on do s and don ts on the inspection day On the day: Don t panic! 15

16 Main points of discussions so far -1 Third party contracts Signal detection Congruence of data in house and communicated to/by authorities Training and knowledge of staff involved in PhV activities Periodicity of literature searches Product defect questions Others? 16

17 Main points of discussions so far - 2 Job descriptions Procedures - presence, content, process Validation, conformity of IT systems to EU requirements for electronic submissions Electronic reporting/importing Third country reporting Availability of local and EU QPs for PhV and their back-up Feasibility of urgent 24 hours safety restriction Training: tests for checking training efficacy 17

18 Variety is the spice of life! Areas for clarification: Purpose of inspections Sometimes part of GMP, or GCP inspections or pure PhV inspection Should all inspections be the same? Or tailored to the activity of the site? Diversity of interpretations of requirements between inspectors Fee? No fee? Per site? Per activities? 18

19 Variety is the spice of life! (continued) Inspectors affiliations Human sector vs Veterinary personnel EMA/CVMP mandated inspections vs National inspections GMP personnel Scope of inspection Focus on SOPs Short and sweet inspections (1 to 2 hours) Full PhV inspections (3 days) Based on the activity of the site? h2 19

20 Folie 19 h2 You could also address EMA inspections vs. country based inspections - how are they different? who would be involved? how they are reported? etc harlow_hl;

21 Conclusions Important event for MAH and others inspected Need careful preparation and follow up If well prepared can be quite rewarding as high visibility event at the MAH Don t become complacent afterwards Always an opportunity to learn and improve! Opportunity to gather more support from management Still fairly new area so likely to evolve to a more structured process? 20

PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector

PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector Content Answer industry questions related to the PSMF MHRA inspector s preparation: How we

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 1 2 3 19 June 2012 EMA/119871/2012 4 5 Guideline on good pharmacovigilance practices (GVP) Module III Pharmacovigilance inspections Draft finalised by the Agency in collaboration with Member States and

More information

Stakeholder Meeting, 17 June 2011, EMA, London. Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency

Stakeholder Meeting, 17 June 2011, EMA, London. Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency New Pharmacovigilance Legislation and Implementing Measures Minimum Requirements for Quality Systems (MAH, EMA, NCA), minimum requirements for Pharmacovigilance System Master File Stakeholder Meeting,

More information

PROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP. Ad Hoc PhV Inspectors Working Group

PROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP. Ad Hoc PhV Inspectors Working Group European Medicines Agency Inspections London, 20 April 2009 EMEA/INS/PhV/85058/2008 Procedure no: INS/PhV-V/2 PROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP Ad Hoc PhV Inspectors

More information

GxP Inspections within the Centralised Procedure. Brendan Cuddy Inspections Sector

GxP Inspections within the Centralised Procedure. Brendan Cuddy Inspections Sector GxP Inspections within the Centralised Procedure Brendan Cuddy Inspections Sector Agenda Introduction to work of the Inspections Sector GxP Inspections within the centralised procedure Regulatory framework

More information

EudraVigilance Vet. and Pharmacovigilance of vet. Medicinal products in Serbia

EudraVigilance Vet. and Pharmacovigilance of vet. Medicinal products in Serbia EudraVigilance Vet. and Pharmacovigilance of vet. Medicinal products in Serbia Presented by: Vladimir Raketić, DVM, spec; Audit /QM group Ministry of Agriculture, Forestry and Water Managment, Veterinary

More information

Post Marketing PV AUDIT AND INSPECTION HOSTING. Michael Ramcharan Reumat Consulting Ejaz Butt ZigZag Associates

Post Marketing PV AUDIT AND INSPECTION HOSTING. Michael Ramcharan Reumat Consulting Ejaz Butt ZigZag Associates Post Marketing PV AUDIT AND INSPECTION HOSTING Michael Ramcharan Reumat Consulting Ejaz Butt ZigZag Associates Agenda Background Preparation Conduct Post Audit & Inspection CAPA Management Audit & Inspection

More information

The APIC Audit Programme Version 5, July 2017

The APIC Audit Programme Version 5, July 2017 The APIC Audit Programme Version 5, July 2017 Table of contents 1 General 2. APIC Audit Programme 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification

More information

Guidelines for Pharmacovigilance Inspections

Guidelines for Pharmacovigilance Inspections PHARMACY BOARD OF SIERRA LEONE Guidelines for Pharmacovigilance Inspections Guideline No. : PBSL/PVGCT/GDL/QPPV/04-2017 Effective Date. :27 th March, 2017 Version No. : 01 1 TABLE OF CONTENT TABLE OF CONTENT

More information

FOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS

FOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS FOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS Document No. : FDA/SMC/SMD/GL-PVI/2013/02 Date of First Adoption : 1 st February, 2013 Date of Issue : 1 st March, 2013

More information

New Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012

New Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012 New Pharmacovigilance legislation Post-authorisation safety studies ENCePP Plenary meeting 3 May 2012 Presented by: Annalisa Rubino, PhV and Risk Management, EMA An agency of the European Union Why? Public

More information

STANDARD OPERATING PROCEDURE TEAM INSPECTIONS

STANDARD OPERATING PROCEDURE TEAM INSPECTIONS PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 031-1 Annex 29 July 2009 STANDARD OPERATING PROCEDURE TEAM INSPECTIONS PIC/S July 2009 Reproduction prohibited for

More information

Procedure management of variations

Procedure management of variations Procedure management of variations Process changes made and current challenges Presented by Alberto Ganan and Iordanis Gravanis on 24 April 2015 Procedure Management Department An agency of the European

More information

Pharmacovigilance System Master file

Pharmacovigilance System Master file IMPLEMENTING MEASURES IN ORDER TO HARMONISE THE PERFORMANCE OF THE PHARMACOVIGILANCE ACTIVITIES PROVIDED FOR IN DIRECTIVE 2001/83/EC AND REGULATION (EC) NO 726/2004 Pharmacovigilance System Master file

More information

Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities

Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities audit, audit report and CAPA 1. QUALITY must be guaranteed,

More information

Electronic exchange of Pharmacovigilance data:

Electronic exchange of Pharmacovigilance data: Electronic exchange of Pharmacovigilance data: the industry journey so far and the look ahead to the future Sylvie Meillerais, IFAH-Europe BVL symposium, Berlin 13-14 December 2010 1 Content IFAH-Europe

More information

Implementation and Impact of the PV Regulations - how are we doing? Sue Rees Eisai Europe Ltd. & John Barber, Dr Reddy's Laboratories

Implementation and Impact of the PV Regulations - how are we doing? Sue Rees Eisai Europe Ltd. & John Barber, Dr Reddy's Laboratories Implementation and Impact of the PV Regulations - how are we doing? Sue Rees Eisai Europe Ltd. & John Barber, Dr Reddy's Laboratories Agenda PSMF PSURs Solicited sources RMPs Inspections Signal detection

More information

Audit of Official Controls in Department of Agriculture, Food and the Marine Approved Poultry (Broiler) Processing (Slaughtering) Establishments

Audit of Official Controls in Department of Agriculture, Food and the Marine Approved Poultry (Broiler) Processing (Slaughtering) Establishments AUDit REPORt Audit of Offi cial Controls in Department of Agriculture, Food and the Marine Approved Poultry (Broiler) Processing (Slaughtering) Establishments Audit REPORT Audit of Official Controls in

More information

Questions And Answers To Support The

Questions And Answers To Support The Questions And Answers To Support The Implementation Of The Pharmacovigilance Legislation - Update This Question and answers section gives advice on regulatory issues in on the interpretation and implementation

More information

CMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES

CMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES CMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES 1. INTRODUCTION (BACKGROUND) November 2007 According to Article 8

More information

Safety reporting requirements in the post marketing phase. Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington

Safety reporting requirements in the post marketing phase. Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington Safety reporting requirements in the post marketing phase Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington DISCLAIMER These materials have been prepared solely for educational

More information

Quality Management in PV. Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017

Quality Management in PV. Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017 Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017 - Pharmacovigilance System - Overall Quality objectives in PV - Quality Management System overview - Quality Management System requirements - Quality

More information

Inspections: an academic perspective

Inspections: an academic perspective Inspections: an academic perspective Patricia Henley Quality and Governance Manager Head, Research Governance & Integrity Office London School of Hygiene & Tropical Medicine Email: patricia.henley@lshtm.ac.uk

More information

Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations

Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations 9th edition of Synevo Clinical Research Symposium. 17 th November 2017 Bucharest.

More information

European Union (EU) Regulatory Trends in GMP. Clive Brading Tianjin, China September 23, 2009

European Union (EU) Regulatory Trends in GMP. Clive Brading Tianjin, China September 23, 2009 European Union (EU) Regulatory Trends in GMP Clive Brading Tianjin, China September 23, 2009 -2- Presentation Topics EU Background Inspections outside the EU EMEA Inspection Outcomes Dedicated Facilities

More information

DJ Cockburn Head of Manufacturing and Quality Compliance European Medicines Agency

DJ Cockburn Head of Manufacturing and Quality Compliance European Medicines Agency Introduction to EU Regulatory system and GMP Inspection system. The Qualified Person. DJ Cockburn Head of Manufacturing and Quality Compliance European Medicines Agency Any views expressed may not necessarily

More information

Journal of Chemical and Pharmaceutical Research

Journal of Chemical and Pharmaceutical Research Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(6):88-98 Conduct of Inspections for Pharmaceutical Manufactures

More information

European Medicines Agency Inspections

European Medicines Agency Inspections European Medicines Agency Inspections London, 14 July 2008 Doc. Ref. EMEA/INS/GMP/361819/2008 COMMUNITY PROJECT ON THE PRACTICAL IMPLEMENTATION OF THE NEW OBLIGATIONS FOR MANUFACTURING AUTHORISATION HOLDERS

More information

SAFETY CULTURE IN ITALY: THE LEGISLATION, INSPECTIONS, THE PERSPECTIVE OF AN INSPECTOR

SAFETY CULTURE IN ITALY: THE LEGISLATION, INSPECTIONS, THE PERSPECTIVE OF AN INSPECTOR SAFETY CULTURE IN ITALY: THE LEGISLATION, INSPECTIONS, THE PERSPECTIVE OF AN INSPECTOR Fabrizio Vazzana ISPRA-Italian National Institute for Environmental Protection and Research AIM: Analyze the dissemination

More information

etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector

etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector Agenda EU Legislation and Guidance News/Updates relating to TMF Structure and Content of e/tmf Inspecting etmfs

More information

The interface between Good Clinical Practice and Good Manufacturing Practice

The interface between Good Clinical Practice and Good Manufacturing Practice 1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who

More information

STRATEGIC PLAN OF THE STATE INSTITUTE FOR DRUG CONTROL FOR Public Section

STRATEGIC PLAN OF THE STATE INSTITUTE FOR DRUG CONTROL FOR Public Section STRATEGIC PLAN OF THE STATE INSTITUTE FOR DRUG CONTROL FOR 2016-2020 Public Section 1 1. FOREWORD The document SÚKL Strategic Plan for 2016-2020 (hereinafter referred to as the Strategy ) summarises the

More information

The new Pharmacovigilance legislation and implementation planning

The new Pharmacovigilance legislation and implementation planning The new Pharmacovigilance legislation and implementation planning Second Stakeholders meeting 17 June 2011 European Medicines Agency, London, UK Presented by: Franck Diafouka Manager, Pharmacovigilance

More information

ENCePP Plenary: New Pharmacovigilance legislation

ENCePP Plenary: New Pharmacovigilance legislation ENCePP Plenary: New Pharmacovigilance legislation 18 November 2010 Peter Arlett Head of Pharmacovigilance and Risk Management EMA An agency of the European Union In this talk 1. New pharmacovigilance legislation:

More information

EMA Comments on Implementing Measures for Pharmacovigilance (PCIM/11/01)

EMA Comments on Implementing Measures for Pharmacovigilance (PCIM/11/01) 7 November 2011 EMA/863255/2011 EMA Comments on Implementing for Pharmacovigilance (PCIM/11/01) The Agency welcomes the public consultation on the Commission concept paper on the implementing measures

More information

Agenda item 4.1 Draft proposal - Notifications of the location of the Pharmacovigilance System Master File (PSMF)

Agenda item 4.1 Draft proposal - Notifications of the location of the Pharmacovigilance System Master File (PSMF) EMA Implementation Working Group with EU Pharmaceutical Industry Associations on the implementation of Article 57(2), second subparagraph of Regulation (EC) 726/2004 Agenda item 4.1 Draft proposal - Notifications

More information

Brexit Guidance for Stakeholders Human and veterinary medicines

Brexit Guidance for Stakeholders Human and veterinary medicines Brexit Guidance for Stakeholders Human and veterinary medicines DATE: 03 JANUARY 2018 V.2 This guide does not purport to be an interpretation of law and/or regulations. The content provided is subject

More information

The APIC Audit Programme Version 3, August 2010

The APIC Audit Programme Version 3, August 2010 The APIC Audit Programme Version 3, August 2010 Table of contents 1 General 2. APIC Audit Program 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification

More information

GVPPG GOOD VETERINARY PHARMACOVIGILANCE PRACTICE GUIDE. The european animal health industry good practice guide to veterinary pharmacovigilance

GVPPG GOOD VETERINARY PHARMACOVIGILANCE PRACTICE GUIDE. The european animal health industry good practice guide to veterinary pharmacovigilance GVPPG GOOD VETERINARY PHARMACOVIGILANCE PRACTICE GUIDE 2 nd edition, APRIL 2011 The european animal health industry good practice guide to veterinary pharmacovigilance [ 3 ] Foreword This IFAH-Europe

More information

PHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use

PHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use PHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use This guideline replaces PHV-3 guideline version 3 effective from 11. 01. 2016 The guideline provides

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 22 June 2012 EMA/816573/2011 Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file Draft finalised by the Agency in collaboration with Member States and submitted

More information

Consultation item no. 1 Should additional processes and pharmacovigilance tasks be covered? No, to our mind the list is complete.

Consultation item no. 1 Should additional processes and pharmacovigilance tasks be covered? No, to our mind the list is complete. Association Européenne des Spécialités Pharmaceutiques Grand Public Association of the European Self-Medication Industry Europäischer Verband der Arzneimittel-Hersteller AESGP Position Paper on the European

More information

Guide to Scientific and Regulatory Advice for GXP activities

Guide to Scientific and Regulatory Advice for GXP activities Guide to Scientific and Regulatory Advice for GXP activities ADV-G0019-1 7 OCTOBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.

More information

GxP Inspections within the Centralised Procedure

GxP Inspections within the Centralised Procedure GxP Inspections within the Centralised Procedure Brendan Cuddy Inspections Sector 2nd EMEA Workshop for Micro, Small and Medium- Sized Enterprises (SMEs) Focus on Quality Agenda Introduction to work of

More information

UK Standards for Pharmacovigilance Departments 2015

UK Standards for Pharmacovigilance Departments 2015 UK Standards for Pharmacovigilance Departments 2015 03 UK Standards for Pharmacovigilance Departments 2015 Introduction 1 European legislation (Directive 2010/84/EU; Regulation (EU) No 1235/2010) requires

More information

CSV Inspection Readiness through Effective Document Control. Eileen Cortes April 27, 2017

CSV Inspection Readiness through Effective Document Control. Eileen Cortes April 27, 2017 CSV Inspection Readiness through Effective Document Control Eileen Cortes April 27, 2017 Agenda Background CSV Readiness CSV and Change Management Process Inspection Readiness Do s and Don ts Inspection

More information

QSS 0 Products and Services without Bespoke Contracts.

QSS 0 Products and Services without Bespoke Contracts. QSS 0 Products and Services without Bespoke Contracts. Use: Typically Sub 50k processes without a bespoke contract. Amendment History Version Date Status V3 June 2018 Updated for 2018 deployment Contents

More information

Data Collection Tools Functions, Indicators & Sub-Indicators

Data Collection Tools Functions, Indicators & Sub-Indicators Data Collection Tools 27- Functions, Indicators & A. National regulatory system Indicator RS1: Legal framework for establishment of a regulatory system, mandate and enforcement power for each function

More information

Period of time from September 2015 to August Summary of pharmacovigilance system audit report results v3

Period of time from September 2015 to August Summary of pharmacovigilance system audit report results v3 Report to the European Commission on Pharmacovigilance audits carried out in BASG/AGES (Austrian Federal Office for Safety in Health Care / Austrian Medicines and Medical Devices Agency), Austria Period

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE

More information

EU Pharmacovigilance Legislation - One Year Later. Sarah Daniels; Senior Partner TranScrip Partners LLP

EU Pharmacovigilance Legislation - One Year Later. Sarah Daniels; Senior Partner TranScrip Partners LLP EU Pharmacovigilance Legislation - One Year Later Sarah Daniels; Senior Partner TranScrip Partners LLP Since July 2012 we have officially been operating under EU legislation Directive 2010/84/EU amending

More information

Explanatory note on general fees payable to the European Medicines Agency

Explanatory note on general fees payable to the European Medicines Agency Explanatory note on general fees payable to the European Medicines Agency The fees, fee exemptions and definitions described in this explanatory note apply as of 1 June 2017 and are based on Council Regulation

More information

Reflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples

Reflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples 1 2 3 26 August 2010 EMA/INS/GCP/532137/2010 GCP Inspectors Working Group 4 5 6 Reflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples Draft Adoption

More information

Work plan for the GMP/GDP Inspectors Working Group for 2018

Work plan for the GMP/GDP Inspectors Working Group for 2018 30 November 2017 EMA/INS/GMP/504401/2017 Inspections, Human Medicines Pharmacovigilance & Committees Division Work plan for the GMP/GDP Inspectors Working Group for 2018 Chairperson: Brendan Cuddy Adopted:

More information

Third Stakeholders forum on the implementation of the new Pharmacovigilance legislation

Third Stakeholders forum on the implementation of the new Pharmacovigilance legislation Safeguarding public health Third Stakeholders forum on the implementation of the new Pharmacovigilance Pharmacovigilance system master file an approach towards system simplification Joanna Harper Inspections,

More information

CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures

CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures October 2017 CMDh/004/2005/Rev.15 CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Table of contents (optional) 1. Introduction... 2 2. Legal framework...

More information

FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE

FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE Document No. : Date of First Adoption : 1st February, 2013 Date of Issue : 1 st March, 2013 Version No. : 02 Revision 1 :

More information

Central Drugs Standard ControlOrganization

Central Drugs Standard ControlOrganization Central Drugs Standard ControlOrganization Directorate General of Health Services Ministry of Health and Family Welfare Government of India Risk based programme for pharmaco-vigilance inspections of market

More information

National self-insurer OHS management system audit tool. Version 3

National self-insurer OHS management system audit tool. Version 3 National self-insurer OHS management system audit tool Version 3 Release Date: 4 August 2014 Next Review Date: 2016 Approval Status: Prepared by: Approved by Heads of Workers Compensation Authorities WorkCover

More information

MASTER VALIDATION PLAN PROCEDURE DRAFT DRAFT OF A POSSIBLE COMPUTER SYSTEMS VALIDATION MASTER PLAN PROCEDURE

MASTER VALIDATION PLAN PROCEDURE DRAFT DRAFT OF A POSSIBLE COMPUTER SYSTEMS VALIDATION MASTER PLAN PROCEDURE DRAFT OF A POSSIBLE COMPUTER SYSTEMS VALIDATION MASTER PLAN PROCEDURE 1. PURPOSE The purpose of this SOP is to define the minimum requirements for Computer Systems Validation (CSV) at (insert name of company

More information

While the recognition

While the recognition Designing the Perfect Change Control System Change control systems today are expected to be designed in a way that provides a system to not only document and approve changes, but also to anticipate change

More information

The European Commission's Proposal to Re-design Existing European Drug Safety Rules. An Industry View on Practical Implications

The European Commission's Proposal to Re-design Existing European Drug Safety Rules. An Industry View on Practical Implications The European Commission's Proposal to Re-design Existing European Drug Safety Rules An Industry View on Practical Implications Margaret Walters Merck, Sharp & Dohme Ltd. The Second International Pharmaceutical

More information

Pharmacovigilance System in India: Industry Perspective

Pharmacovigilance System in India: Industry Perspective Pharmacovigilance System in India: Industry Perspective Dr. Jamal Baig, Global Pharmacovigilance Country Leader, MSD Pharmaceutical Pvt. Ltd., India. Introduction Currently there are 3 major PV guidelines

More information

Explanatory Note to GVP Module VII

Explanatory Note to GVP Module VII 31 October 2017 EMA/670256/2017 Human Medicines Evaluation Division Explanatory Note to GVP Module VII Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA), the procedure

More information

Regulatory Compliance Inspections at MAH Offices: Implications for Manufacturers

Regulatory Compliance Inspections at MAH Offices: Implications for Manufacturers Regulatory Compliance Inspections at MAH Offices: Implications for Manufacturers Kevin O Donnell, Ph.D. Market Compliance Manager GMP & Market Compliance Info Day September 2012 Slide 1 What are Regulatory

More information

Internal Auditing and Control of Nonconforming Work

Internal Auditing and Control of Nonconforming Work Internal Auditing and Control of Nonconforming Work ISO/IEC 17025, clauses 4.14 and 4.9 www.aphl.org What will be covered in this training? Internal Auditing What is it? Who performs it? What are the possible

More information

INTER-AGENCY JOB MARKET VACANCY NOTICE EMSA/IAJM/AD/2016/02

INTER-AGENCY JOB MARKET VACANCY NOTICE EMSA/IAJM/AD/2016/02 INTER-AGENCY JOB MARKET VACANCY NOTICE EMSA/IAJM/AD/2016/02 In order to promote the mobility of Temporary Agents across Agencies, the European Maritime Safety Agency (EMSA) wishes to inform Temporary Agents

More information

HANDBOOK OF PUBLIC SECTOR PROCUREMENT PROCEDURES (MAY, 2001)

HANDBOOK OF PUBLIC SECTOR PROCUREMENT PROCEDURES (MAY, 2001) GOVERNMENT OF JAMAICA HANDBOOK OF PUBLIC SECTOR PROCUREMENT PROCEDURES (MAY, 2001) National Contracts Commission 17 Knutsford Boulevard Kingston 5 Jamaica, West Indies http://www.ocg.gov.jm Acknowledgements

More information

AMF Position Compliance function requirements

AMF Position Compliance function requirements AMF Position 2012-17 Compliance function requirements Reference texts: Articles 313-1 to 313-3, 313-5 to 313-7, 313-54, 313-75 of the AMF General Regulation The Autorité des Marchés Financiers applies

More information

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO 23 August 2017 EMA/431267/2016 Annex IV to guidance for the conduct of good clinical practice inspections sponsor Adopted by GCP Inspectors Working Group (GCP IWG) 29 November 2017 Keywords GCP inspection,

More information

Audit REPORt. Audit of Offi cial Controls Carried Out at Local Authority Approved Slaughterhouses Galway County Council

Audit REPORt. Audit of Offi cial Controls Carried Out at Local Authority Approved Slaughterhouses Galway County Council Audit REPORt Audit of Offi cial Controls Carried Out at Local Authority Approved Slaughterhouses Audit REPORT Audit of Official Controls Carried Out at Local Authority Approved Slaughterhouses Table of

More information

Pharmacovigilance Officer (m/f) Ref. 2011/10/132

Pharmacovigilance Officer (m/f) Ref. 2011/10/132 Pharmacovigilance Officer (m/f) Ref. 2011/10/132 Our client, a leading European pharmaceutical company is looking to recruit an Pharmacovigilance Officer (m/f) for their Head Office in Luxembourg. Major

More information

Module VIII- Post-authorisation safety studies

Module VIII- Post-authorisation safety studies Good Vigilance Practice Module VIII- Post-authorisation safety studies 4th Stakeholder Forum Xavier Kurz An agency of the European Union Post-authorisation safety study Any study relating to an authorised

More information

Supervision of manufacturers: What is expected of National Competent Authorities?

Supervision of manufacturers: What is expected of National Competent Authorities? Supervision of manufacturers: What is expected of National Competent Authorities? Fergus Sweeney, PhD, European Medicines Agency Head, Compliance and Inspections EU 28: Science, Medicines, Health Dubrovnik,

More information

Annex II: Evaluation Procedure

Annex II: Evaluation Procedure Making the railway system work better for society. NSA Monitoring 1 / 22 Procedure Evaluation procedure for the NSA monitoring activity Document Type: Procedure Origin: ERA Document ID: Activity Based

More information

COMMISSION REGULATION (EU)

COMMISSION REGULATION (EU) 17.11.2012 Official Journal of the European Union L 320/3 COMMISSION REGULATION (EU) No 1077/2012 of 16 November 2012 on a common safety method for supervision by national safety authorities after issuing

More information

Q/A-LIST FOR THE SUBMISSION OF VARIATIONS ACCORDING TO COMMISSION REGULATION (EC) 1234/2008

Q/A-LIST FOR THE SUBMISSION OF VARIATIONS ACCORDING TO COMMISSION REGULATION (EC) 1234/2008 Q/A-LIST FOR THE SUBMISSION OF VARIATIONS ACCORDING TO COMMISSION REGULATION (EC) 1234/2008 1. General questions Doc. Ref: CMDh/132/2009/Rev.20 May 2013 Question 1.1 What is the definition of MAH? According

More information

Re: PCIM/11/01 Public Consultation on Implementing Measures for Pharmacovigilance

Re: PCIM/11/01 Public Consultation on Implementing Measures for Pharmacovigilance 07 November 2011 By email: sanco pharmaceuticals@ec.europa.eu Directorate General for Health and Consumers Unit SANCO/D/3 BE 1049 Brussels Belgium Dear Sirs, Re: PCIM/11/01 Public Consultation on Implementing

More information

Signal Management in the EU and future extended access to EudraVigilance for industry

Signal Management in the EU and future extended access to EudraVigilance for industry Signal Management in the EU and future extended access to EudraVigilance for industry 6 th Industry Stakeholder Platform Meeting, 18 th December 2015 Presented by Georgy Genov 7 December 2015 Head of Signal

More information

Presenter: Ejaz Butt

Presenter: Ejaz Butt Presenter: Ejaz Butt Disclaimer The content and opinions expressed in the following PowerPoint slides are those of individuals who prepared the presentation and should not be attributed to Zigzag Associates

More information

NIS Considerations - Bulgaria

NIS Considerations - Bulgaria NIS Considerations - Bulgaria An overview of the considerations when conducting Noninterventional Studies in Bulgaria Stuart McCully CHCUK Ltd NIS-C-BG-2014 1 Table of Contents Disclaimer 5 Copyright 5

More information

1. GLOSSARY EXECUTIVE SUMMARY INTRODUCTION Audit Objective Audit Scope... 5

1. GLOSSARY EXECUTIVE SUMMARY INTRODUCTION Audit Objective Audit Scope... 5 Audit REPORt Audit of offi cial controls in food business operations catering for high-risk population groups supervised by environmental health offi cers in the Health Service Executive Audit REPORT Audit

More information

Inspection of API Manufacturers & Update on Registration Process

Inspection of API Manufacturers & Update on Registration Process Inspection of API Manufacturers & Update on Registration Process Catherine Neary, GMP Inspector GMP Conference 7 February 2017 Dublin Presentation Contents HPRA Inspection Programme for API Manufacturers

More information

TABLE OF CONTENTS 1.0 INTRODUCTION...

TABLE OF CONTENTS 1.0 INTRODUCTION... Advisory Circular Subject: Quality Assurance Programs Issuing Office: Civil Aviation, Standards Document No.: AC QUA-001 File Classification No.: Z 5000-34 Issue No.: 01 RDIMS No.: 9376810-V14 Effective

More information

Industry perspective: Non-prescription medicines

Industry perspective: Non-prescription medicines EMA 7 th Stakeholders forum on the implementation of the new pharmacovigilance legislation 27 September 2013 Industry perspective: Non-prescription medicines Introduction Perfect timing for a review Comprehensive

More information

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience Umberto Filibeck Former Head of AIFA GCP Inspectorate and GCP Promotion Unit UNICRI Consultant for Projects on GCP of CTs in developing

More information

Agency and Internal Labeling

Agency and Internal Labeling Agency and Internal Labeling Audits Joseph McMillian, MA Heartland Compliance Services LLC Internal Labeling Audits The views and opinions expressed in the following PowerPoint slides are those of the

More information

PREPARING A CLIENT FOR INVESTIGATIONS

PREPARING A CLIENT FOR INVESTIGATIONS PREPARING A CLIENT FOR INVESTIGATIONS INVESTIGATIONS Investigations Can Involve: - Industry or Sector Wide Investigation - Targeting a Company or Group of Companies - Unannounced Inspections ( Dawn Raids

More information

COMMISSION RECOMMENDATION. of XXX. on the audits and assessments performed by notified bodies in the field of medical devices

COMMISSION RECOMMENDATION. of XXX. on the audits and assessments performed by notified bodies in the field of medical devices EUROPEAN COMMISSION Brussels, XXX [ ](2013) XXX draft COMMISSION RECOMMENDATION of XXX on the audits and assessments performed by notified bodies in the field of medical devices (Text with EEA relevance)

More information

WELMEC Application of module D Quality assurance Under directive 2014/32/EU (MID) or directive 2014/31/EU (NAWID)

WELMEC Application of module D Quality assurance Under directive 2014/32/EU (MID) or directive 2014/31/EU (NAWID) WELMEC 8.4 2017 Application of module D Quality assurance Under directive 2014/32/EU (MID) or directive 2014/31/EU (NAWID) WELMEC is a cooperation between the legal metrology authorities of the Member

More information

Q&A - Pharmacovigilance Legislation

Q&A - Pharmacovigilance Legislation CMDh/257/2012, Rev.18 July 2017 Regulation (EU) No 1235/2010 and Directive 2010/84/EU Table of contents 1. a. As of 21 July 2012, new requirements for marketing authorisation applications have been introduced

More information

Pharmacovigilance System in Russia and the EAEU

Pharmacovigilance System in Russia and the EAEU Pharmacovigilance System in Russia and the EAEU Authors: Sergey Simeniv CEO X7 Research, CRO; Olga Latysheva Head of Pharmacovigilance Department X7 Research, CRO; Dmitry Kryuchkov Executive Director X7

More information

Functioning of the PRAC

Functioning of the PRAC Functioning of the PRAC Sixth Stakeholders forum on the implementation of the new Pharmacovigilance legislation, November 8 th 2012 Presented by: Almath Spooner Vice Chair, Pharmacovigilance Risk Assessment

More information

UNANNOUNCED EU MEDICAL DEVICE AUDITS BY NOTIFIED BODIES: IMPACT ON SUPPLIERS

UNANNOUNCED EU MEDICAL DEVICE AUDITS BY NOTIFIED BODIES: IMPACT ON SUPPLIERS UNANNOUNCED EU MEDICAL DEVICE AUDITS BY NOTIFIED BODIES: IMPACT ON SUPPLIERS Executive Summary European Medicines Agency (EMA) regulations for licensing of medical devices include the use of authorized

More information

Recent developments in Pharmacovigilance from the Regulator s Perspective. In strategy, competence, quality and flexibility

Recent developments in Pharmacovigilance from the Regulator s Perspective. In strategy, competence, quality and flexibility Recent developments in Pharmacovigilance from the Regulator s Perspective In strategy, competence, quality and flexibility Pharmacovigilance Regulatory Affairs Operations Medical Writing & toxicology Recent

More information

COMMON MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION: RULES OF GOOD CLINICAL PRACTICE AND GOOD LABORATORY PRACTICE

COMMON MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION: RULES OF GOOD CLINICAL PRACTICE AND GOOD LABORATORY PRACTICE COMMON MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION: RULES OF GOOD CLINICAL PRACTICE AND GOOD LABORATORY PRACTICE www.gratanet.com Among other regulations aimed at the implementation of the Agreement

More information

Guideline on Good Pharmacovigilance Practices Module V- Pharmacovigilance System Master File

Guideline on Good Pharmacovigilance Practices Module V- Pharmacovigilance System Master File Guideline on Good Pharmacovigilance Practices Module V- Pharmacovigilance System Master File Turkish Medicines and Medical Devices Agency 16.02.2015 CHAPTER I... 2 1.1. Introduction... 2 CHAPTER II...

More information

QUMU CLOUD PLATFORM CUSTOMER SUPPORT AGREEMENT

QUMU CLOUD PLATFORM CUSTOMER SUPPORT AGREEMENT QUMU CLOUD PLATFORM CUSTOMER SUPPORT AGREEMENT I. DEFINITIONS "Approved Support Contacts" means CUSTOMER employees that are authorized to initiate Support Requests with QUMU Customer Support and that are

More information

Work plan for the GMP/GDP Inspectors Working Group for 2017

Work plan for the GMP/GDP Inspectors Working Group for 2017 13 January 2017 EMA/INS/GMP/584202/2016 Work plan for the GMP/GDP Inspectors Working Group for 2017 Chairperson: David Cockburn Adopted: December 2016 1. Meetings scheduled for 2017 Face-to-face meetings

More information